Skip to main content
Top
Published in: Indian Journal of Pediatrics 4/2013

01-04-2013 | Clinical Brief

HIV Genotype Resistance Testing in Antiretroviral (ART) Exposed Indian Children—A Need of the Hour

Authors: Ira Shah, Shefali Parikh

Published in: Indian Journal of Pediatrics | Issue 4/2013

Login to get access

Abstract

Development of drug resistance in HIV infected children with treatment failure is a major impediment to selection of appropriate therapy. HIV genotype resistance assays predict drug resistance on the basis of mutations in the viral genome. However, their clinical utility, especially in a resource limited setting is still a subject of debate. The authors report two cases in which both the children suffered from treatment failure of various antiretroviral therapy regimes. In both the cases, Genotype Resistance Testing (GRT) prompted a radical change from proposed failure therapy as per existing guidelines. GRT was specifically important for the selection of a new dual Nucleoside reverse transcriptase inhibitors (NRTI) component of failure regimen by identifying TAMS and M184V mutations in the HIV genome. These case reports highlight the importance of GRT in children failing multiple antiretroviral regimes; and emphasizes the need to recognize situations where GRT is absolutely essential to guide appropriate therapy, even in a resource limited setting.
Literature
1.
go back to reference Deshpande A, Karki S, Recordon-Pinson P, Fleury HJ. Drug resistance mutations in HIV type 1 isolates from naive patients eligible for first line antiretroviral therapy in JJ Hospital, Mumbai, India. AIDS Res Hum Retroviruses. 2011;27:1345–7.PubMedCrossRef Deshpande A, Karki S, Recordon-Pinson P, Fleury HJ. Drug resistance mutations in HIV type 1 isolates from naive patients eligible for first line antiretroviral therapy in JJ Hospital, Mumbai, India. AIDS Res Hum Retroviruses. 2011;27:1345–7.PubMedCrossRef
2.
go back to reference Sen S, Tripathy SP, Patil AA, Chimanpure VM, Paranjape RS. High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses. 2007;23:1303–8.PubMedCrossRef Sen S, Tripathy SP, Patil AA, Chimanpure VM, Paranjape RS. High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses. 2007;23:1303–8.PubMedCrossRef
3.
go back to reference Vidya M, Saravanan S, Uma S, et al. Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. Antivir Ther. 2009;14:1005–9.PubMedCrossRef Vidya M, Saravanan S, Uma S, et al. Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. Antivir Ther. 2009;14:1005–9.PubMedCrossRef
4.
go back to reference Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected withhuman immunodeficiency virus type 1. Women and infants transmission study group. N Engl J Med. 1997;336:1337–42.PubMedCrossRef Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected withhuman immunodeficiency virus type 1. Women and infants transmission study group. N Engl J Med. 1997;336:1337–42.PubMedCrossRef
5.
go back to reference Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16:209–18.PubMedCrossRef Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16:209–18.PubMedCrossRef
6.
go back to reference Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002;16:369–79.PubMedCrossRef Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002;16:369–79.PubMedCrossRef
7.
go back to reference Clevenbergh P, Durant J, Halfon P, et al. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The viradapt study: week 48 follow-up. Antivir Ther. 2000;5:65–70.PubMed Clevenbergh P, Durant J, Halfon P, et al. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The viradapt study: week 48 follow-up. Antivir Ther. 2000;5:65–70.PubMed
8.
go back to reference Kumarasamy N, Madhavan V, Venkatesh K, et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis. 2009;49:306–9.PubMedCrossRef Kumarasamy N, Madhavan V, Venkatesh K, et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis. 2009;49:306–9.PubMedCrossRef
Metadata
Title
HIV Genotype Resistance Testing in Antiretroviral (ART) Exposed Indian Children—A Need of the Hour
Authors
Ira Shah
Shefali Parikh
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Indian Journal of Pediatrics / Issue 4/2013
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-012-0752-6

Other articles of this Issue 4/2013

Indian Journal of Pediatrics 4/2013 Go to the issue

Correspondence

IgM Nephropathy